Logo image of IKNA

IKENA ONCOLOGY INC (IKNA) Stock Fundamental Analysis

USA - NASDAQ:IKNA - US45175G1085 - Common Stock

1.43 USD
+0.06 (+4.38%)
Last: 7/25/2025, 8:00:01 PM
1.46 USD
+0.03 (+2.1%)
After Hours: 7/25/2025, 8:00:01 PM
Fundamental Rating

3

Overall IKNA gets a fundamental rating of 3 out of 10. We evaluated IKNA against 191 industry peers in the Pharmaceuticals industry. IKNA has a great financial health rating, but its profitability evaluates not so good. IKNA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year IKNA has reported negative net income.
IKNA had a negative operating cash flow in the past year.
IKNA had negative earnings in each of the past 5 years.
IKNA had a negative operating cash flow in each of the past 5 years.
IKNA Yearly Net Income VS EBIT VS OCF VS FCFIKNA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M -60M -80M

1.2 Ratios

Looking at the Return On Assets, with a value of -34.79%, IKNA is in line with its industry, outperforming 48.97% of the companies in the same industry.
IKNA has a Return On Equity (-39.10%) which is in line with its industry peers.
Industry RankSector Rank
ROA -34.79%
ROE -39.1%
ROIC N/A
ROA(3y)-36.73%
ROA(5y)-30.05%
ROE(3y)-42.01%
ROE(5y)-36.93%
ROIC(3y)N/A
ROIC(5y)N/A
IKNA Yearly ROA, ROE, ROICIKNA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for IKNA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IKNA Yearly Profit, Operating, Gross MarginsIKNA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K

More info and screens

7

2. Health

2.1 Basic Checks

IKNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for IKNA remains at a similar level compared to 1 year ago.
The number of shares outstanding for IKNA has been increased compared to 5 years ago.
IKNA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IKNA Yearly Shares OutstandingIKNA Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
IKNA Yearly Total Debt VS Total AssetsIKNA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

IKNA has an Altman-Z score of -2.95. This is a bad value and indicates that IKNA is not financially healthy and even has some risk of bankruptcy.
IKNA has a Altman-Z score of -2.95. This is comparable to the rest of the industry: IKNA outperforms 44.33% of its industry peers.
IKNA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.95
ROIC/WACCN/A
WACC9.74%
IKNA Yearly LT Debt VS Equity VS FCFIKNA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M 200M

2.3 Liquidity

A Current Ratio of 11.80 indicates that IKNA has no problem at all paying its short term obligations.
The Current ratio of IKNA (11.80) is better than 85.05% of its industry peers.
IKNA has a Quick Ratio of 11.80. This indicates that IKNA is financially healthy and has no problem in meeting its short term obligations.
IKNA has a Quick ratio of 11.80. This is amongst the best in the industry. IKNA outperforms 85.05% of its industry peers.
Industry RankSector Rank
Current Ratio 11.8
Quick Ratio 11.8
IKNA Yearly Current Assets VS Current LiabilitesIKNA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for IKNA have decreased strongly by -121.62% in the last year.
The Revenue for IKNA has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)-121.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-157.14%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

IKNA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.75% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y41.43%
EPS Next 2Y17.21%
EPS Next 3Y7.65%
EPS Next 5Y14.75%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IKNA Yearly Revenue VS EstimatesIKNA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2029 2030 2031 2032 50M 100M
IKNA Yearly EPS VS EstimatesIKNA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

IKNA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IKNA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IKNA Price Earnings VS Forward Price EarningsIKNA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IKNA Per share dataIKNA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.21%
EPS Next 3Y7.65%

More info and screens

0

5. Dividend

5.1 Amount

IKNA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IKENA ONCOLOGY INC

NASDAQ:IKNA (7/25/2025, 8:00:01 PM)

After market: 1.46 +0.03 (+2.1%)

1.43

+0.06 (+4.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)07-24 2025-07-24/amc
Earnings (Next)11-05 2025-11-05/bmo
Inst Owners65.17%
Inst Owner Change0%
Ins Owners0.12%
Ins Owner Change0%
Market Cap15.99M
Revenue(TTM)N/A
Net Income(TTM)-49234000
Analysts82.5
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)12.38%
Min EPS beat(2)1.96%
Max EPS beat(2)22.8%
EPS beat(4)4
Avg EPS beat(4)16.83%
Min EPS beat(4)1.96%
Max EPS beat(4)22.8%
EPS beat(8)7
Avg EPS beat(8)11.97%
EPS beat(12)9
Avg EPS beat(12)7.82%
EPS beat(16)12
Avg EPS beat(16)-2.9%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-33.33%
PT rev (3m)-33.33%
EPS NQ rev (1m)-1100%
EPS NQ rev (3m)-1100%
EPS NY rev (1m)0%
EPS NY rev (3m)28.83%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.13
P/tB 0.13
EV/EBITDA N/A
EPS(TTM)-3.28
EYN/A
EPS(NY)-0.63
Fwd EYN/A
FCF(TTM)-4.11
FCFYN/A
OCF(TTM)-4.11
OCFYN/A
SpS0
BVpS11.26
TBVpS11.26
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -34.79%
ROE -39.1%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-36.73%
ROA(5y)-30.05%
ROE(3y)-42.01%
ROE(5y)-36.93%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.8
Quick Ratio 11.8
Altman-Z -2.95
F-Score3
WACC9.74%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-121.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-157.14%
EPS Next Y41.43%
EPS Next 2Y17.21%
EPS Next 3Y7.65%
EPS Next 5Y14.75%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y27.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-66.37%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y42.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y42.31%
OCF growth 3YN/A
OCF growth 5YN/A